Table 3.
Patient outcome.
| Intraoperative ultrasound (n=23) | Resection under standard neuronavigation (n=24) | p value | |
|---|---|---|---|
| IDH mutation | 0.494 | ||
| Mutated | 0 (0%) | 0 (0%) | |
| Wildtype | 19 (83%) | 17 (71%) | |
| Unknown | 4 (17%) | 7 (29%) | |
| MGMT promotor methylation | 0.347 | ||
| Methylated | 6 (26%) | 7 (29%) | |
| Unmethylated | 13 (57%) | 9 (38%) | |
| Unknown | 4 (17%) | 8 (33%) | |
| Adjuvant therapy | 0.148 | ||
| None | 3 (13%) | 2 (8%) | |
| Chemo or radiotherapy | 3 (13%) | 0 (0%) | |
| Chemoradiation* | 17 (74%) | 22 (92%) | |
| NIHSS post-operative, median (IQR) |
0 (0-2) | 0 (0-2) | 0.825 |
| KPS after surgery, median (IQR) |
|||
| Seven weeks | 90 (90-100) | 90 (80-100) | 0.412 |
| Three months | 90 (80-100) | 90 (70-100) | 0.540 |
| Six months | 90 (70-90) | 70 (60-90) | 0.228 |
| Quality of life change, baseline vs. six months** |
|||
| Global health status | -2 (35) | -14 (28) | 0.344 |
| Physical functioning | -8 (31) | -13 (18) | 0.267 |
| Cognitive functioning | -11 (32) | -2 (30) | 0.893 |
| Motor dysfunction | 2 (21) | 5 (20) | 0.893 |
| Communication deficit | 1 (26) | -6 (22) | 0.609 |
| Overall survival, median (95% CI), days |
377 (247-507) | 372 (320-424) | 0.751 |
| Progression-free survival, median (95% CI), days | 227 (107-347) | 233 (153-313) | 0.937 |
Data are n or n (%), unless stated otherwise. *Stupp protocol **A change of ≥10 points is considered to be clinically relevant.
KPS, Karnofsky performance status; IDH, isocitrate dehydrogenase; MGMT, methylguanine; DNA, methyltransferase; NIHSS, National Institutes of Health stroke score.